𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B

✍ Scribed by M. Sayan; S.C. Akhan

Book ID
118452531
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
79 KB
Volume
16
Category
Article
ISSN
1201-9712

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of hepatitis B vaccine against
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model
✍ Saleem Kamili; Vitini Sozzi; Geoff Thompson; Katie Campbell; Christopher M. Walk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Hepatitis B virus (HBV) mutants resistant to treatment with nucleoside or nucleotide analogs and those with the ability to escape from HBV-neutralizing antibody have the potential to infect HBV-vaccinated individuals. To address this potential serious public health challenge, we tested the efficacy

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Absence of hepatitis B virus precore mut
Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α
✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni

Dane Particle-Associated Hepatitis B e A
Dane Particle-Associated Hepatitis B e Antigen in Patients with Chronic Hepatitis B Virus Infection and Hepatitis B e Antibody
✍ Giovanni Raimondo; Serafino Recchia; Carla Lavarini; Osvaldo Crivelli; Mario Riz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

A commercial radioimmunoassay was adapted to detect serum Dane particle-associated HBeAg in patients whose sera contained the homologous antibody. HBeAg was released from Dane particles with guanidine HC1. Dane particles were separated from anti-HBe by gel-filtration (Sepharose 4B) and ultracentrif